Phase 3 Encephalitis Clinical Trials
4 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–4 of 4 trials
Recruiting
Phase 3
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
NMDAR Autoimmune EncephalitisLGI1 Autoimmune Encephalitis
Hoffmann-La Roche152 enrolled93 locationsNCT05503264
Recruiting
Phase 3
Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis
Anti-N-Methyl-D-Aspartate Receptor Encephalitis
The First People's Hospital of Changzhou200 enrolled2 locationsNCT06867991
Not Yet Recruiting
Phase 3
Long Term Immunogenicity of the JE Vaccine IC51
Prophylactic Vaccine against Japanese Encephalitis
Intercell AG600 enrolled1 locationACTRN12605000681651
Not Yet Recruiting
Phase 3
Safety and Tolerability Study of the JE Vaccine IC51
Prophylactic Vaccine against Japanese Encephalitis
Intercell AG600 enrolled1 locationACTRN12605000680662